- Home
- ABTC vs CRBP Comparison
ABTC vs CRBP Comparison
Compare ABTC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTC
- CRBP
- Stock Information
- Founded
- ABTC 2024
- CRBP 2009
- Country
- ABTC United States
- CRBP United States
- Employees
- ABTC N/A
- CRBP N/A
- Industry
- ABTC EDP Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- ABTC Technology
- CRBP Health Care
- Exchange
- ABTC Nasdaq
- CRBP Nasdaq
- Market Cap
- ABTC 122.5M
- CRBP 114.8M
- IPO Year
- ABTC N/A
- CRBP N/A
- Fundamental
- Price
- ABTC N/A
- CRBP $9.89
- Analyst Decision
- ABTC
- CRBP Strong Buy
- Analyst Count
- ABTC 0
- CRBP 10
- Target Price
- ABTC N/A
- CRBP $53.22
- AVG Volume (30 Days)
- ABTC 15.8M
- CRBP 97.4K
- Earning Date
- ABTC 11-08-2025
- CRBP 11-06-2025
- Dividend Yield
- ABTC N/A
- CRBP N/A
- EPS Growth
- ABTC N/A
- CRBP N/A
- EPS
- ABTC N/A
- CRBP N/A
- Revenue
- ABTC N/A
- CRBP N/A
- Revenue This Year
- ABTC N/A
- CRBP N/A
- Revenue Next Year
- ABTC N/A
- CRBP $220.04
- P/E Ratio
- ABTC N/A
- CRBP N/A
- Revenue Growth
- ABTC N/A
- CRBP N/A
- 52 Week Low
- ABTC $6.24
- CRBP $4.64
- 52 Week High
- ABTC $14.52
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- ABTC N/A
- CRBP 56.38
- Support Level
- ABTC N/A
- CRBP $9.50
- Resistance Level
- ABTC N/A
- CRBP $10.17
- Average True Range (ATR)
- ABTC 0.00
- CRBP 0.59
- MACD
- ABTC 0.00
- CRBP -0.02
- Stochastic Oscillator
- ABTC 0.00
- CRBP 56.74
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.